Glaxosmi. Pharma
Glaxosmi. Pharma Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
GSK India targets sustained double-digit growth in coming quarters, aiming for 13-14% CAGR to achieve INR 8,000 crores revenue in 4-5 years. GSK India aims for sustained double-digit top-line growth, targeting around 13%-14% CAGR to reach INR 8,000 crores in 4-5 years. - Growth drivers include both the large established general medicines business (expected to grow 8%-10%) and innovative specialty products (high-growth segments like oncology and respiratory). - Innovation portfolio contribution has doubled recently to 7% of total revenues, materially impacting growth. - EBITDA growth ran slightly ahead of sales with a 17% increase vs.
From Glaxosmi. Pharma's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- GSK India targets sustained double-digit growth in coming quarters, aiming for 13-14% CAGR to achieve INR 8,000 crores revenue in 4-5 years.
- Growth drivers include innovation portfolio growing from 4% to 7% of sales, with oncology, new respiratory, and adult vaccines leading.
- General medicines remain relevant, expected to grow 8-10%.
- Oncology is a fastest-growing segment (industry growth 27% vs. 12-13% overall), providing significant uplift.
- Innovation assets like Shingrix (+65% growth), Nucala (doubling new patients treated), and Trelegy Ellipta continue strong momentum.
- New launches such as Jemperli, Zejula, Blenrep, Ojjaara, and Arexvy expected to contribute to growth.
- Front-loaded investments in marketing and scientific engagement aim to sustain growth.
- Volume growth blended at ~3-3.5%, price growth ~6%, with new introductions contributing significantly.
Profitability & Margins
See what Glaxosmi. Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The transcript does not explicitly mention specific current or future capex or capital investments.
- However, there is significant investment in front-loading activities such as medical oncologist speaker programs and evidence generation, which likely involve capital allocation towards marketing and scientific dissemination.
- The company is focused on building and scaling innovative portfolios like oncology, respiratory, and vaccines, implying ongoing strategic investments.
- Manufacturing capacity includes a setup in Nashik for local production of general medicines, with 20 contract manufacturers supplementing production, indicating capital investment in local manufacturing infrastructure.
- No explicit mention of new plant or large capital expenditure projects was made.
- Focus remains on portfolio transformation and efficiency improvements, which might include IT and operational investments for process simplification.
- Overall, investments appear targeted towards innovation launches, marketing, and supply chain readiness rather than large fixed asset expansions at this stage.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Glaxosmi. Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Glaxosmi. Pharma — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹995 Cr, net profit ₹278 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Glaxosmithkline Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Glaxosmi. Pharma Q1 FY27 results?
GSK India targets sustained double-digit growth in coming quarters, aiming for 13-14% CAGR to achieve INR 8,000 crores revenue in 4-5 years. GSK India aims for sustained double-digit top-line growth, targeting around 13%-14% CAGR to reach INR 8,000 crores in 4-5 years. - Growth drivers include both the large established general medicines business (expected to grow 8%-10%) and innovative specialty products (high-growth segments like oncology and respiratory). - Innovation portfolio contribution has doubled recently to 7% of total revenues, materially impacting growth. - EBITDA growth ran slightly ahead of sales with a 17% increase vs.
What is Glaxosmi. Pharma share price analysis?
Glaxosmi. Pharma currently shows a below-average growth signal. The stock trades at a P/E of 46.7 with a market cap of ₹49,165 Cr. Investors should review the full earnings analysis for detailed insights.
Is Glaxosmi. Pharma planning capital expenditure?
The transcript does not explicitly mention specific current or future capex or capital investments.
Keep Glaxosmi. Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.